The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Open accessAbstract
The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene correction in patient-derived haematopoietic stem cells followed by autologous transplantation could be used to cure β-haemoglobinopathies. Here we present a CRISPR/Cas9 gene-editing system that combines Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous donor to achieve homologous recombination at the HBB gene in haematopoietic stem cells. Notably, we devise an enrichment model to purify a population of haematopoietic stem and progenitor cells with more than 90% targeted integration. We also show efficient correction of the Glu6Val mutation responsible for sickle cell disease by using patient-derived stem and progenitor cells that, after differentiation into erythrocytes, express adult β-globin (HbA) messenger RNA, which confirms intact transcriptional regulation of edited HBB alleles. Collectively, these preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, several reports have shown efficient Glu6Val correction in SCD-HSPCs, although correction efficiency can sometimes be linked with off-target INDELs in the same edited population15,16,45,46.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RNP delivery results in an initially high level of the genome editing machinery followed by rapid decay, leading to a “fast on, fast off” strategy that results in highly efficient editing while minimizing OTEs13–19.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major progress in delivering to 44 and handling HPSCs has resulted in formidable efficiencies of mutation correction or mitigation 18,45-47 that are expected to be curative.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
In the citing paper
“Furthermore, CRISPR/Cas9 system holds tremendous promise for gene therapy [46–51]. It can correct causal mutations in the original genome and rescue the disease phenotypes of monogenic disorders permanently, which currently represents the most translatable field in CRISPR/Cas9-mediated disease therapy.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Self-citationIsolation of a candidate human hematopoietic stem-cell population.
Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A., & Péault, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2804 · Cited by 1,084
Hematopoietic stem cell: self‐renewal versus differentiation
Seita, J., & Weissman, I. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.86 · Cited by 997
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 864
CRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Li, R., Wang, Q., She, K., Lu, F., & Yang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00095-y · Cited by 13
A culture platform to study quiescent hematopoietic stem cells following genome editing
Shiroshita, K., Kobayashi, H., Watanuki, S., Karigane, D., Sorimachi, Y., Fujita, S., Tamaki, S., Haraguchi, M., Itokawa, N., Aoyama, K., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100354 · Cited by 12
Chatterjee, S., Bhattacharya, M., Lee, S., & Chakraborty, C. (2023) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2023.100150 · Cited by 12
Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease
Bhatt, S., Argueta, D. A., Gupta, K., & Kundu, S. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0348 · Cited by 13
Sato, Y., Osada, E., & Manome, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22911 · Cited by 12
Pugliano, C. M., Berger, M. P., Ray, R. M., Sapkos, K., Wu, B., Laird, A., Ye, Y., Thomson, D., DeGottardi, M. Q., Khan, I., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101297 · Cited by 12
Chu, S. N., Soupène, E., Sharma, D., Sinha, R., McCreary, T., Hernandez, B. N., Shen, H., Wienert, B., Bowman, C., Yin, H., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115141 · Cited by 12
Self-citationFeist, W. N., Luna, S. E., Ben-Efraim, K., Interrante, M. V. F., Amorin, A., Johnston, N. M., Bruun, T. U. J., Utz, A., Ghanim, H. Y., Lesch, B. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58371-8 · Cited by 15
Self-citationGenome Editing in Stem Cells for Disease Therapeutics
Song, M., & Ramakrishna, S. (2018) · Molecular Biotechnology · doi:10.1007/s12033-018-0072-9 · Cited by 13
Chen, H.-M., Resendes, R., Ghodssi, A., Sookiasian, D., Tian, M., Dollive, S., Adamson-Small, L. A., Avila, N., Tazearslan, C., Thompson, J. F., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233373 · Cited by 13
Zhu, M., Huangfu, C., Wan, W., Wang, M., Lv, H., Zhang, X., Wang, F., Zhi, H., Huang, Y., Chen, M., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c05315 · Cited by 12
Modarai, S., Man, D., Bialk, P. A., Rivera-Torres, N., Bloh, K. M., & Kmiec, E. B. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.01.013 · Cited by 12
Diamond–Blackfan anemia RPL35A: a case report
Noel, C. B. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2127-3 · Cited by 12
Development of gene editing strategies for human β-globin (HBB) gene mutations
Kalkan, B. M., Kala, E. Y., Yüce, M., Alpaslan, M. K., & Kocabaş, F. (2020) · Gene · doi:10.1016/j.gene.2020.144398 · Cited by 11
Recent advances in stem cells and gene editing: Drug discovery and therapeutics
Bayarsaikhan, D., Bayarsaikhan, G., & Lee, B. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.019 · Cited by 12
Gene Therapy as the New Frontier for Sickle Cell Disease
Garg, H., Tatiossian, K. J., Peppel, K., Kato, G. J., & Herzog, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210527092456 · Cited by 12
Gene Therapy for Primary Immunodeficiency
Houghton, B., & Booth, C. (2021) · UCL Discovery (University College London) · Cited by 12
A Practical Guide to Genome Editing Using Targeted Nuclease Technologies
Porter, S. N., Levine, R. M., & Pruett‐Miller, S. M. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180022 · Cited by 18
Sun, J. Q. J., Elliott, M. R., & Souza-Fonseca-Guimarães, F. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70045 · Cited by 12
Gene editing-based targeted integration for correction of Wiskott-Aldrich syndrome
Pille, M., Avila, J. M., Park, S. H., Le, C. Q., Xue, H., Haerynck, F., Saxena, L., Lee, C. M., Shpall, E. J., Bao, G., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101208 · Cited by 11
Kanke, K. L., Rayner, R. E., Bozik, J., Abel, E., Venugopalan, A., Suu, M., Nouri, R., Stack, J. T., Guo, G., Vetter, T. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1069 · Cited by 13
Precise measurement of CRISPR genome editing outcomes through single-cell DNA sequencing
Kalter, N., Gulati, S., Rosenberg, M., Ayaz, Q., Nguyen, J., Wang, S., Schroeder, B., Li, C.-Y., & Hendel, A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101449 · Cited by 15
Self-citationThe Cas9 Hammer—and Sickle: A Challenge for Genome Editors
Urnov, F. D. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.29120.fur · Cited by 11
Bchetnia, M., Gagné, R. D., Powell, J., Morin, C., McCuaig, C. C., Dupéré, A., Germain, L., Tremblay, J. P., & Laprise, C. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0132 · Cited by 11
Wolff, J. H., & Mikkelsen, J. G. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1148650 · Cited by 12
Disease Modeling of Neuropsychiatric Brain Disorders Using Human Stem Cell-Based Neural Models
Kaindl, J., & Winner, B. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_111 · Cited by 12
Shilo, N. R., & Morris, C. R. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1364989 · Cited by 12
Qi, T., Fu, J., Zhang, W., Cui, W., Xu, X., Yue, J., Wang, Q., & Tian, X. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2118 · Cited by 10
Cheng, X., Cao, Y., Duan, J., Zhou, M., Ye, S., & Zhu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00318-y · Cited by 12
CRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome
Ravendran, S., Hernández, S. S., König, S., & Bak, R. O. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.793010 · Cited by 11
Self-citationSari, O., Liu, Z., Pan, Y., & Shao, X. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbae184 · Cited by 12
Engineering Globin Gene Expression
Davis, R., Gurumurthy, A., Hossain, M. A., Gunn, E. M., & Bungert, J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.004 · Cited by 10
Development and challenges of using CRISPR-Cas9 system in mammalians
Khambhati, K., Gohil, N., Bhattacharjee, G., & Singh, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00007-6 · Cited by 10
Mikuni, T., & Uchigashima, M. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14734 · Cited by 11
CRISPR-Cas Systems: Prospects for Use in Medicine
Zaychikova, M. V., Даниленко, В. Н., & Maslov, D. A. (2020) · Applied Sciences · doi:10.3390/app10249001 · Cited by 10
Ureña-Bailén, G., Block, M., Grandi, T., Aivazidou, F., Quednau, J., Krenz, D., Daniel-Moreno, A., Lamsfus‐Calle, A., Epting, T., Handgretinger, R., et al. (2023) · The CRISPR Journal · doi:10.1089/crispr.2022.0086 · Cited by 11
Feng, Y.-L., Liu, S., Chen, R.-D., Sun, X., Xiao, J., Xiang, J.-F., & Xie, A. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad116 · Cited by 10
Arulmozhivarman, G., Kräter, M., Wobus, M., Friedrichs, J., Bejestani, E. P., Müller, K., Lambert, K., Alexopoulou, D., Dahl, A., Stöter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12360-0 · Cited by 10
Barnett, P. (2017) · Science & Technology Libraries · doi:10.1080/0194262x.2017.1394248 · Cited by 10
Ctrl-Alt-inDel: genome editing to reprogram a cell in the clinic
Urnov, F. D. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.05.005 · Cited by 11
Rare immune diseases paving the road for genome editing-based precision medicine
Pavel-Dinu, M., Borna, Š., & Bacchetta, R. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1114996 · Cited by 10
Self-citationInnovative Therapies for Hemoglobin Disorders
Sii-Felice, K., Nègre, O., Brendel, C., Tubsuwan, A., Morel-à-l’Huissier, E., Filardo, C., & Payen, E. (2020) · BioDrugs · doi:10.1007/s40259-020-00439-6 · Cited by 10
Genome Editing for Sickle Cell Disease: A Little BCL11A Goes a Long Way
Hossain, M. A., & Bungert, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.003 · Cited by 10
Genome Editing Revolution in Life Sciences
Singh, A. K., Ramalingam, S., Rao, D. N., & Chandrasegaran, S. (2021) · Resonance · doi:10.1007/s12045-021-1195-z · Cited by 9
CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice
Frederiksen, H. R. S., Glantz, A., Vøls, K. K., Skov, S., Tveden‐Nyborg, P., Freude, K., & Doehn, U. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1403395 · Cited by 9
Treating genetic blood disorders in the era of CRISPR-mediated genome editing
Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.031 · Cited by 11
Shahid, A., Zahra, A., Aslam, S., Shamim, A., Ali, W. R., Aslam, B., Khan, S. H., & Arshad, M. I. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01374-z · Cited by 13
Butt, H., Sathish, S., London, E., Johnson, T. L., Essawi, K., Leonard, A. K., Tisdale, J. F., & Demirci, S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.047 · Cited by 12
Butt, H., Mandava, M., & Jacobsohn, D. A. (2025) · The CRISPR Journal · doi:10.1089/crispr.2024.0101 · Cited by 9
Methods for detecting off-target effects of CRISPR/Cas9
Xu, Y., Zhou, S., Wang, L.-Y., Zhang, R., Li, K., Qian, Z., & Li, X. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108750 · Cited by 11
Basic and Clinical Application of Adeno-Associated Virus–Mediated Genome Editing
He, X., Xie, H., Liu, X., & Gu, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.190 · Cited by 7
Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders
Buffa, V., Vargas, J. R. A., Galy, A. H. M., Spinozzi, S., & Rocca, C. J. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.997142 · Cited by 10
Enrichment of transgene integrations by transient CRISPR activation of a silent reporter gene
Mikkelsen, N. S., Hernández, S. S., Jensen, T. I., Schneller, J. L., & Bak, R. O. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.010 · Cited by 9
Self-citationDelivery platforms for broadly neutralizing antibodies
Joshi, L. R., Gálvez, N. M. S., Ghosh, S., Weiner, D. B., & Balazs, A. B. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000803 · Cited by 10
Genome editing for sickle cell disease: still time to correct?
Ceglie, G., Lecis, M., Canciani, G., Algeri, M., & Frati, G. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1249275 · Cited by 14
In situ correction of various β-thalassemia mutations in human hematopoietic stem cells
Yang, Y., He, L., Xie, Y., Zhu, L., Wu, J., Fan, Y., Yang, Y., & Sun, X. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1276890 · Cited by 10
Janns, J. H., & Mikkelsen, J. G. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.105 · Cited by 10
May, A. P. (2017) · Nature Biotechnology · doi:10.1038/nbt.3871 · Cited by 9
Wooley, D. P., Sharma, P., Weinstein, J. R., Narayan, P. K. L., Schaffer, D. V., & Excoffon, K. J. D. A. (2017) · Journal of Virological Methods · doi:10.1016/j.jviromet.2017.09.008 · Cited by 10
Blood Relatives: Splicing Mechanisms underlying Erythropoiesis in Health and Disease
Reimer, K. A., & Neugebauer, K. M. (2018) · F1000Research · doi:10.12688/f1000research.15442.1 · Cited by 9
CRISPR/Cas9 applications in gene therapy for primary immunodeficiency diseases
Ravin, S. S. D., & Brault, J. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180157 · Cited by 9
Koyunlar, C., & de Pater, E. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.602182 · Cited by 10
β-Hemoglobinopathies: The Test Bench for Genome Editing-Based Therapeutic Strategies
Barbarani, G., Łabędź, A., & Ronchi, A. E. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.571239 · Cited by 8
CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
Karapurkar, J. K., Antao, A. M., Kim, K.-S., & Ramakrishna, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.018 · Cited by 11
Design of experiments as a decision tool for cell therapy manufacturing
Lee, E., Shah, D., Porteus, M. H., Wright, J. F., & Bacchetta, R. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.01.009 · Cited by 9
Self-citationTargeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight
Zhang, Z., Zhang, S., Wong, H. T., Li, D., & Feng, B. (2024) · BioDrugs · doi:10.1007/s40259-024-00654-5 · Cited by 9
Stack, J. T., Rayner, R. E., Nouri, R., Suarez, C. J., Kim, S. H., Kanke, K. L., Vetter, T. A., Cormet‐Boyaka, E., & Vaidyanathan, S. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102339 · Cited by 8
Wallace, K. A., Gerstenberg, T. L., Ennis, C. L., Pérez-Bermejo, J. A., Partridge, J. R., Bandoro, C., Matern, W. M., Andreoletti, G., Krassovsky, K., Kabir, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.036 · Cited by 8
Self-citationHarnessing CRISPR potential for intervertebral disc regeneration strategies
Milheiro, C., Moura, M. L., Amendola, M., Barbosa, M. A., & Caldeira, J. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1562412 · Cited by 10
Pache, M. M., Pangavhane, R. R., Nikam, S. V., Rode, R. B., & Darekar, A. B. (2025) · Research Journal of Science and Technology · doi:10.52711/2231-5713.2025.00045 · Cited by 8
Strategies and mechanisms of precision genome engineering: From gene editing to genome writing
Huang, K., Tian, J., Zhao, W., Zhang, S., Xiang, L., Yang, M., Ls, L., Huang, Y., Zhang, N., Sun, L., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70115 · Cited by 8
Toward In Vivo Gene Therapy Using CRISPR
Skipper, K. A., & Mikkelsen, J. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9170-9_18 · Cited by 8
Cosenza, L. C., Zuccato, C., Zurlo, M., Gambari, R., & Finotti, A. (2022) · Genes · doi:10.3390/genes13101727 · Cited by 8
Moço, P. D., Farnós, O., Sharon, D. M., & Kamen, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100486 · Cited by 8
Ding, L., Chen, D., Li, Y., Xie, Y., Sun, X., & Wang, D. (2024) · Human Cell · doi:10.1007/s13577-024-01034-5 · Cited by 8
Pérez-Bermejo, J. A., Efagene, O., Matern, W. M., Holden, J. K., Kabir, S., Chew, G. M., Andreoletti, G., Catton, E., Ennis, C. L., Garcia, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46816-5 · Cited by 8
Self-citationPrasad, K. M., Devaraju, N., George, A., Ravi, N. S., Paul, J., Mahalingam, G., Rajendiran, V., Panigrahi, L., Venkatesan, V., Lakhotiya, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102205 · Cited by 10
Gene therapy strategies for RAG1 deficiency: Challenges and breakthroughs
Gilioli, G., Lankester, A. C., de Kivit, S., Staal, F. J. T., & de Bruin, L. M. O. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106931 · Cited by 8
Babu, P., Azhagiri, M. K. K., Venkatesan, V., Magis, W., Prasad, K. M., Suresh, S., Pai, A. A., Marepally, S. K., Srivastava, A., Mohankumar, K. M., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04117-0 · Cited by 9
CRISPR Editing in Biological and Biomedical Investigation
Zhang, H., & McCarty, N. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26111 · Cited by 9
Glanzmann’s thrombasthenia: strategies for identification and management
Poon, M., Minno, G. D., Zotz, R. B., & d’Oiron, R. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1341306 · Cited by 8
Gene therapy: Erasing sickle-cell disease
Bourzac, K. (2017) · Nature · doi:10.1038/549s28a · Cited by 8
Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency
Abdul-Razak, H. H., Rocca, C. J., Howe, S. J., Alonso-Ferrero, M. E., Wang, J., Gabriel, R., Bartholomae, C. C., Gan, V. C. H., Garin, M. I., Roberts, A. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26439-9 · Cited by 7
Shapiro, J., Tovin, A., Iancu, O., Allen, D. G., & Hendel, A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0687-2_3 · Cited by 8
Self-citationParameters affecting successful stem cell collections for genetic therapies in sickle cell disease
Justus, D. G., & Manis, J. P. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103059 · Cited by 9
Random-PE: an efficient integration of random sequences into mammalian genome by prime editing
Jiao, Y., Zhou, L., Tao, R. X., Wang, Y., Hu, Y. F., Jiang, L., Li, L., & Yao, S. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00057-w · Cited by 8
Vojnits, K., Nakanishi, M., Porras, D. P., Kim, Y., Feng, Z., Golubeva, D., & Bhatia, M. (2022) · Molecules · doi:10.3390/molecules27082434 · Cited by 10
Liu, Y., Schmiderer, L., Hjort, M., Lang, S., Bremborg, T., Rydström, A., Schambach, A., Larsson, J., & Karlsson, S. (2023) · Haematologica · doi:10.3324/haematol.2022.282068 · Cited by 8
Genetic Therapies for Sickle Cell Disease
Jayavaradhan, R., & Malik, P. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.008 · Cited by 8
Pipeline for the generation of gene knockout mice using dual sgRNA CRISPR/Cas9-mediated gene editing
Ghassemi, B., Shamsara, M., Soleimani, M., Kiani, J., & Rassoulzadegan, M. (2018) · Analytical Biochemistry · doi:10.1016/j.ab.2018.12.002 · Cited by 8
Ouagrham-Gormley, S. B., & Fye-Marnien, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-03053-7_12 · Cited by 8
Ghosh, D., Kumar, A., & Sinha, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820595-2.00006-0 · Cited by 8
Wegrzyn, R. D., Lee, A. H., Jenkins, A. L., Stoddard, C. D., & Cheever, A. E. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00689 · Cited by 8
Martin, R. M., Ikeda, K., Uchida, N., Cromer, K., Nishimura, T., Dever, D. P., Camarena, J., Bak, R. O., Laustsen, A., Jakobsen, M. R., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/252163 · Cited by 8
Self-citationRecent Research Trends in Stem Cells Using CRISPR/Cas-Based Genome Editing Methods
Yoon, D. E., Lee, H., & Kim, K. (2023) · International Journal of Stem Cells · doi:10.15283/ijsc23030 · Cited by 8
Recent advances and applications of the CRISPR-Cas system in the gene therapy of blood disorders
Zanganeh, S., Zahedi, A. M., Bardsiri, M. S., Bazı, A., Bastanifard, M., Shool, S., Kouhbananinejad, S. M., Farsinejad, A., Afgar, A., Shahabi, A., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148865 · Cited by 7
Andersen, S., Wolff, J. H., Skov, T. W., Janns, J. H., Davis, L., Haldrup, J., Haslund, D., Revenfeld, A. L., Relkovic, D., Møller, B. K., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf767 · Cited by 7
Self-citationTanhehco, Y. C., Thibodeaux, S. R., Shi, P. A., Chou, S. T., Kelly, S., Monis, G. F., Newton, C., West, K. A., Zheng, Y., Fernandez, C. M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016054 · Cited by 8
High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion
de Menezes, M. N., Chen, A. X. Y., Kulkarni, N., Sampurno, S., Saw, N. Y. L., Yap, K. M., Pérez-Núñez, I., Roth, S., Deguit, C., Haugen, B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69671-y · Cited by 7
Innovations in CRISPR-Based Therapies
Kesavan, G. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00411-x · Cited by 7
Metadata
- Authors
- Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., Uchida, N., Hendel, A., Narla, A., Majeti, R., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford University (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Stanford Medicine (US)
- Corresponding author
- Porteus, Matthew H.
- ORCID
- Venue
- Nature
- Published
- 2016-11-07
- Volume
- 539
- Issue
- 7629
- Pages
- 384-389
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5898607
- OpenAlex
- W2547418311
- Semantic Scholar
- 91eb4c33902b14df9b2974a4ce8dc6e3c3a02125
- Cited by
- 864
- References
- 50
- Citations by year
- 2026: 45 · 2025: 75 · 2024: 80 · 2023: 93 · 2022: 76 · 2021: 120 · 2020: 93 · 2019: 90 · 2018: 99 · 2017: 89 · 2016: 4
- FWCI
- 48.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ai120766-02, R01-AI120766)
- National Eye Institute (PN2EY018244)
- National Institute of General Medical Sciences (T32GM007266)
- National Institute of Allergy and Infectious Diseases (R01-AI120766, R01AI097320)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- CRISPR/Cas9 genome editing, beta-globin gene, hematopoietic stem cells, sickle cell disease, beta-thalassemia, homologous recombination, adeno-associated virus vectors, Cas9 ribonucleoprotein, autologous transplantation, reporter genes
- MeSH terms
- Gene Editing, Dependovirus, Alleles, Anemia, Sickle Cell, Animals, Cell Differentiation, Cell Separation, Erythrocytes, Female, Flow Cytometry, Hematopoietic Stem Cells, Humans, Microspheres, Mutation, RNA, Messenger, Genetic Therapy, Mice, SCID, Mice, Inbred NOD, beta-Thalassemia, Genes, Reporter, Gene Targeting, Antigens, CD34, Cell Lineage, beta-Globins, Magnets, Homologous Recombination, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
